What is CorMedix's revenue?

CorMedix (CRMD) generated $400.1M in revenue over the trailing twelve months, up 384.6% year over year.

Is CorMedix profitable?

CorMedix reported $181.0M in net income over the trailing twelve months, a 45.2% net margin.

What are CorMedix's profit margins?

Gross margin is 91.9% and operating margin is 48.4%, with a 45.2% net margin.

What is CorMedix's earnings per share?

CorMedix's diluted EPS over the trailing twelve months is $2.04.

Where does CorMedix's income statement data come from?

Every line is extracted from CorMedix's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

CorMedix CRMD Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Depreciation and amortization	$24.34M+75.8%	$13.84M+269%	$3.76M+1,706%	$207.95K+11.7%	$186.12K+19.3%
Net income	$181.01M+11.0%	$163.06M—	——	——	——
Amortization Of Intangibles	$24.12M+73.9%	$13.87M+267%	$3.78M+1,720%	$207.95K—	——
Foreign currency translation	——	-$100K-33.3%	-$75K-50.0%	-$50K-100%	-$25K—
Accounts Receivable, Allowance for Credit Loss, Writeoff	——	$18K—	——	——	——
Amortization Of Financing Costs	——	$398K—	——	——	——
Book Value Of Raw Materials	——	$0—	——	——	——
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1	——	$6.5M—	——	——	——
Conversion Of Stock Amount Issued1	——	$49.29M—	——	——	——
Cumulative Translation Adjustment Net Of Tax Period Increase Decrease	——	-$84K—	——	——	——
Federal	——	$2.72M—	——	——	——
Current State And Local Tax Expense Benefit	——	$10.04M+39.8%	$7.18M+66.1%	$4.32M+195%	$1.46M+205%
Federal	——	-$28.88M—	——	——	——
Deferred taxes	——	——	——	——	——
State	——	$3.09M—	——	——	——
Discount Rate	——	——	——	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	——	——	——	——	——
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate	——	——	——	——	——
Foreign operations	——	——	——	——	——
Nontaxable or nondeductible items	——	——	——	——	——
Effective Income Tax Rate Reconciliation Officer Compensation	——	$1.65M+24.9%	$1.32M+33.2%	$989K+49.7%	$660.5K+98.9%
Effective Income Tax Rate Reconciliation Officers Compensation Percent	——	——	——	——	——
Excess tax benefits associated with employee equity plans (in percent)	——	——	——	——	——
Excess tax benefits associated with employee equity plans	——	-$851K-215%	-$270K-187%	$311K-65.1%	$892K-39.4%
State income taxes – net of federal income tax benefit	——	——	——	——	——
Effective Income Tax Rate Reconciliation, Tax Credit, Percent	——	——	——	——	——
Effective Income Tax Rate Reconciliation Transaction Cost	——	$2.12M—	——	——	——
Effective Income Tax Rate Reconciliation Transactions Cost Percent	——	——	——	——	——
Effective Income Tax Rate Reconciliationt Change In Fair Value Of Contingent Liability Percent	——	——	——	——	——
Fair Value Of Assets Acquired From Melinta	——	$513.98M—	——	——	——
Unrealized Gain (Loss), Foreign Currency Transaction, before Tax	——	$86K—	——	——	——
Goodwill Recognized On Melinta	——	$30M—	——	——	——
Income Loss From Continuing Operations Before Income Taxes Domestic	——	$150.02M+39.2%	$107.75M+64.6%	$65.48M+182%	$23.2M+222%
Income Loss From Continuing Operations Before Income Taxes Foreign	——	——	——	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	——	-$60.71M-33.8%	-$45.37M-51.1%	-$30.02M-105%	-$14.67M-2,274%
Income Tax Reconciliation Foreign Income Tax Rate Differential	——	——	——	——	——
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	——	$31.5M+39.3%	$22.61M+64.8%	$13.72M+184%	$4.83M+219%
Nontaxable or Nondeductible items	——	$507K+18.8%	$426.75K+23.2%	$346.5K+30.1%	$266.25K+43.1%
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount	——	$936K+32.5%	$706.25K+48.2%	$476.5K+93.1%	$246.75K+1,351%
Income Tax Reconciliation Prior Year Income Taxes	——	$79K-79.7%	$388.75K-44.3%	$698.5K-30.7%	$1.01M-23.5%
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount	——	$10.37M+39.6%	$7.43M+65.5%	$4.49M+190%	$1.55M+211%
Income Taxes Paid, Net	——	$62K+29.2%	$48K+41.2%	$34K+70.0%	$20K+233%
Accounts payable	——	——	——	——	——
Increase (Decrease) in Accounts Receivable	$71.51M-21.3%	$90.92M-19.5%	$112.93M+164%	$42.84M—	——
Accrued liabilities	$49.82M-50.6%	$100.77M+58.8%	$63.47M+251%	$18.11M-29.6%	$25.73M+12.0%
Increase Decrease In Deferred Liabilities	——	$1.37M—	——	——	——
Increase (Decrease) in Inventories	$4.6M+32.4%	$3.48M-4.1%	$3.63M-35.5%	$5.62M+8.8%	$5.17M-5.9%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	——
Interest Paid, Excluding Capitalized Interest, Operating Activity	$2.82M+16,512%	$17K-35.3%	$26.28K-27.6%	$36.29K+0.3%	$36.17K+0.5%
Liabilities Assumed From Melinta	——	$45.43M—	——	——	——
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	$221.68M-7.6%	$239.87M-4.5%	$251.15M+119%	$114.69M+253%	$32.51M+23.5%
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	-$308.57M+1.0%	-$311.73M0.0%	-$311.73M-2,113%	-$14.09M-214%	$12.4M-42.4%
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	$197.69M+12.9%	$175.05M+133%	$74.97M+146%	$30.46M+325%	-$13.57M+73.2%
Other Noncash Income (Expense)	-$861K-242%	-$252K-12.9%	-$223.25K-14.8%	-$194.5K-17.3%	-$165.75K-21.0%
Other income, net	——	——	——	——	——
Payment for Contingent Consideration Liability, Financing Activities	$663.75K+251%	$189K—	——	——	——
Payment Of Contingent Consideration Liabilities Operating Activities	——	$61K—	——	——	——
Payments For Merger Related Costs	——	$10.2M—	——	——	——
Payment, Tax Withholding, Share-Based Payment Arrangement	$2.5M+25.6%	$1.99M+11.4%	$1.78M+35.2%	$1.32M+8.9%	$1.21M+318%
Payments to Acquire Property, Plant, and Equipment	$2.98M+31.8%	$2.26M+311%	$550.04K+918%	$54.03K-16.7%	$64.87K-44.1%
Payments to Acquire Short-Term Investments	$37.97M-20.8%	$47.95M-9.8%	$53.17M+17.5%	$45.23M+55.7%	$29.06M+8.6%
Proceeds from Issuance of Common Stock	——	——	——	——	——
Short-term investments sold	$49.19M-11.0%	$55.29M-2.5%	$56.69M+83.5%	$30.9M-25.0%	$41.22M-14.3%
Cash received from option exercises	$7.22M+13.0%	$6.39M-25.9%	$8.63M-4.3%	$9.01M—	——
Revenue From Contract With Customer Excluding Assessed Tax	——	——	——	——	——
Right Of Use Asset Obtained Exchange For Finance Lease Liability	——	$203K—	——	——	——
Stock-based compensation	$14.91M+7.8%	$13.83M+20.9%	$11.44M+33.0%	$8.6M+19.7%	$7.19M+17.2%
Stock-based compensation, shares issued during period (in shares)	——	——	——	——	——
Stock Issued During Period Value In Connection With ATM Sale Of Common Stock Net	——	$7.79M-26.3%	$10.56M-20.8%	$13.34M-17.2%	$16.11M-14.7%
Stock Issued During Period Value In Connection With The Exercise Of Prefunded Warrants	——	——	——	——	——
Undistributed Earnings	——	$988K—	——	——	——
Undistributed Earnings Loss Available To Common Shareholders Basic	——	-$162.07M-38.4%	-$117.07M-62.4%	-$72.07M-166%	-$27.07M-251%
EBITDA	$218.58M+32.7%	$164.66M—	——	——	——
EBIT	$193.67M+29.0%	$150.14M—	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about CorMedix.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CorMedix's revenue?: CorMedix (CRMD) generated $400.1M in revenue over the trailing twelve months, up 384.6% year over year.
Is CorMedix profitable?: CorMedix reported $181.0M in net income over the trailing twelve months, a 45.2% net margin.
What are CorMedix's profit margins?: Gross margin is 91.9% and operating margin is 48.4%, with a 45.2% net margin.
What is CorMedix's earnings per share?: CorMedix's diluted EPS over the trailing twelve months is $2.04.
Where does CorMedix's income statement data come from?: Every line is extracted from CorMedix's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.